• Home
  • Journal
  • Public Companies
  • CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil

CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil

VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer, Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer and Harish Seethamraju, M.D., Medical Director for the Mount Sinai Lung Transplantation Program, will host an investment community webcast on Monday, March 8, 2021.
Management will discuss the data from the recently completed Phase 3 trial for severe-to-critically ill COVID-19 patients, the regulatory path forward with several countries, as well as updates on other clinical and corporate priorities.Management will provide approximately 90 minutes to address questions submitted online by analysts and investors.Date: Monday, March 8, 2021
Time: 1:00 pm PT / 4:00 pm ET
Dial-In: None.
Questions:
Prior to the webcast, questions can be submitted online to CYDY_Team@cytodyn.comDuring the webcast, questions can be submitted through the webcast link below.This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. Please note the below website will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/44014/indexl.htmlThe replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until April 8, 2021.CONTACTS
Investors:
Michael Mulholland
Office: 360.980.8524, ext. 102
mmulholland@cytodyn.com

Disclaimer & Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.